Current and Future Perspectives on Migraine Prevention Therapy

Program Overview

Characteristics of Migraine

Current Migraine Prevention Treatment

Adherence to Migraine Prevention Treatment

Medication Overuse Headache: EFNS Headache Panel Guideline

CGRP Elevation in Migraine Attacks

Release of Perivascular Neuropeptides During Acute Primary Headache Attacks

CGRP Receptor Mechanisms

Acute Treatment With CGRP Receptor Blockers and Migraine Headache Relief

Effect of CGRP mAbs on Episodic Migraine: Phase 2 Trials with Different Populations and Regimens

50% Responder Rate in Phase 2 Trial of AMG334

Monoclonal Antibodies Targeting the CGRP Pathway

Findings for CGRP in SAH

Adverse Events With CGRP mAbs in Phase 2 Studies

CGRP, the Trigeminal Ganglion, and the Blood Brain Barrier

Other Areas for Research

Concluding Remarks

Abbreviations